Volume 10 Number 2 2026
Covalent and mutant-selective EGFR inhibitor design in non-small-cell lung cancer
Ibrahim Al-Deeb1*, Nozlena A Samad 1, KZ Khor 1, Heshu Rahman 2, Julia Joseph1,
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210962
Submitted: 27 May 2026 Revised: 19 July 2026 Accepted: 28 July 2026 Published: 30 July 2026
Somatic activating mutations in the epidermal growth factor receptor (EGFR) transformed lung adenocarcinoma from an empirically treated disease into the defining case study of precision oncology, yet each therapeutic advance has been followed, with some regularity, by a resistance mechanism that the advance itself selected for. This review traces the medicinal-chemistry logic connecting three generations of EGFR tyrosine kinase inhibitors (TKIs), and argues that the field’s central lesson is not that covalent chemistry works, but that covalent reactivity and mutant selectivity are separable design properties that had to be solved independently. First-generation reversible inhibitors exploited a narrow biophysical accident — activating mutations lower the receptor’s affinity for ATP — which the T790M gatekeeper substitution then reversed in roughly half of all progressions. Second-generation agents answered the competition problem with an electrophilic acrylamide warhead that alkylates Cys797, but retained a quinazoline core blind to the distinction between mutant and wild-type receptor; the resulting cutaneous and gastrointestinal toxicity, not insufficient potency, capped their dose below therapeutic exposure. Only when the core was rebuilt as a mono-anilinopyrimidine did covalent engagement and roughly hundred-fold wild-type sparing coexist in one molecule, a combination that delivered the FLAURA, AURA3 and ADAURA results and unusually good central nervous system activity. Resistance has since moved on rather than disappeared: tertiary C797S, whose tractability depends almost entirely on allelic phase, alongside MET amplification, bypass receptor signalling, and lineage or phenotypic switching that no kinase inhibitor addresses. We synthesise structural, pharmacological and clinical evidence across these generations, map the post-osimertinib landscape, and consider what fourth-generation allosteric inhibitors, bispecific antibodies and antibody–drug conjugates can plausibly contribute.
Keywords: epidermal growth factor receptor; non-small-cell lung cancer; covalent inhibitor; osimertinib; T790M; C797S; acquired resistance; mutant selectivity
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, F., Thomson, S., Du, S., Chandler, W. B., Biroc, S. L., Buck, E., Arnold, L. D., & Gibson, N. W. (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Research, 66(16), 8163–8171.
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Miller, V. A., Michor, F., & Pao, W. (2011). Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine, 3(90), Article 90ra59.
Costa, D. B., Nguyen, K. S., Cho, J. A., Giaccone, G., & Tenen, D. G. (2008). Gefitinib monotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 62(1), 101–108.
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., & Jänne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), 1039–1043.
Fukui, T., Mitsudomi, T., & Yatabe, Y. (2020). EGFR mutation testing and driver mutations in non-small cell lung cancer. Frontiers in Genetics, 11, Article 281.
Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y. K., Cobo, M., Kasahara, K., & Cheng, Y. (2019). Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clinical Cancer Research, 25(22), 6644–6652.
Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., & Nishio, M. (2015). Spatiotemporal T790M heterogeneity in non-small cell lung cancer patients with acquired resistance to EGFR-TKIs. Journal of Thoracic Oncology, 10(11), 1553–1559.
Herbst, R. S., Wu, Y. L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., & Kim, S. W. (2023). Adjuvant osimertinib for resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer: Updated results from the randomized phase III ADAURA trial. Journal of Clinical Oncology, 41(10), 1830–1840.
Johnson, M., Garassino, M. C., Mok, T., & Mitsudomi, T. (2022). Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 170, 41–51.
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 352(8), 786–792.
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K. T., Cejas, P., Portell, A., & Jänne, P. A. (2020). Treatment-induced tumor dormancy and persistence in EGFR-mutant non-small cell lung cancer. Cancer Cell, 37(1), 104–122.
Lee, Y., Lee, G. K., Lee, Y. S., Zhang, W., Hwang, J. A., Nam, B. H., & Kim, J. H. (2017). Clinical outcomes of different EGFR TKIs in EGFR-mutant non-small cell lung cancer: Successes and challenges. Journal of Thoracic Oncology, 12(5), 790–802.
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019). Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer, 121(9), 725–737.
Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S., & AURA3 Investigators. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. The New England Journal of Medicine, 376(7), 629–640.
Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., & Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 361(10), 947–957.
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015). The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clinical Cancer Research, 21(17), 3924–3933.
Pao, W., & Chmielecki, J. (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 10(11), 760–774.
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M., Arcila, M., Arrieta, O., Planchard, D., de Marinis, F., & Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of Oncology, 33(5), 466–487.
Passaro, A., Mok, T., Peters, S., Jänne, P. A., & de Marinis, F. (2019). Intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Mechanisms and clinical implications. Cancers, 11(7), Article 923.
Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., & Sequist, L. V. (2018). Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discovery, 8(12), 1529–1539.
Pretelli, G., Pretelli, C. C., Ciappina, G., Santarpia, M., & Pasello, G. (2023). Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need. International Journal of Molecular Sciences, 24(10), 8878.
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., & FLAURA Investigators. (2018). CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. Journal of Clinical Oncology, 36(33), 3290–3297.
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Cardenal, F., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., & EURTAC Investigators. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239–246.
Sequist, L. V., Han, J. Y., Ahn, M. J., Cho, B. C., Yu, H. A., Kim, S. W., Yang, J. C., Cantarini, M., Jänne, P. A., & Oxnard, G. R. (2020). Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study. The Lancet Oncology, 21(3), 373–386.
Sequist, L. V., Yang, J. C., Yamamoto, N., O’Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C. M., Boyer, M., & Su, W. C. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3327–3334.
Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., & FLAURA Investigators. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. The New England Journal of Medicine, 378(2), 113–125.
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., & Ercan, D. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560–562.
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., & Su, W. C. (2023). Overall survival with osimertinib in resected EGFR-mutated NSCLC. The New England Journal of Medicine, 389(2), 137–147.
Vaclova, T., Grazini, U., Ward, L., O’Neill, D., Markovets, A., Huang, X., Chmielecki, J., Hartmaier, R., Thress, K. S., Smith, P. D., Barrett, J. C., Downward, J., & de Bruin, E. C. (2021). Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications, 12(1), Article 1780.
Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Kunnimalaiyaan, S., Thomas, S. M., Yousem, S. A., & Burns, T. F. (2019). TWIST1 is required for EGFR TKI resistance in EGFR-mutant non-small-cell lung cancer. Oncogene, 38(5), 656–670.
Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., & Eck, M. J. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences, 105(6), 2070–2075.
Yun, J., Hong, M. H., Kim, S. Y., Park, C. W., Kim, S., Yun, M. R., Kang, H. N., Pyo, K. H., Lee, S. S., Koh, J. S., Song, H. J., Kim, D. K., Lee, Y. S., Oh, S. W., Choi, S., Kim, H. R., & Cho, B. C. (2019). YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clinical Cancer Research, 25(8), 2575–2587.
Zhang, Y., Zhao, Y., Lu, S., & Chen, J. (2025). Neoadjuvant aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: A single-arm phase II trial. Nature Communications, 16(1), Article 2843.
Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., Zheng, S., Wang, J., Lu, Y., Yuan, Z., & OPTIMAL Investigators. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. The Lancet Oncology, 12(8), 735–742.
Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., & Jänne, P. A. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 462(7276), 1070–1074.
Allosteric and covalent strategies for RAS-driven cancers from KRAS G12C to pan-RAS inhibition